Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
Type:
Grant
Filed:
July 5, 2018
Date of Patent:
November 2, 2021
Assignees:
Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd., Olivia Newton-John Cancer Research Institute
Inventors:
Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
October 26, 2021
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
October 26, 2021
Assignee:
KODIAK SCIENCES INC.
Inventors:
Daniel Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
Abstract: The present invention provides methods of detecting increased carcinoembryonic antigen-related cell adhesion molecule (CEACAM) protein expression in a biological sample from a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene. The invention also provides methods of treating or preventing inflammatory bowel disease (IBD) in a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
October 19, 2021
Assignee:
The Regents of the University of California
Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.
Abstract: Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.
Abstract: The present invention provides an antibody or antibody fragment thereof for a targeted cytomembrane voltage-gated sodium channel ? subunit Nav1.9. The specific binding target is a S3-4 ring of a voltage sensor paddle of a domain II of the voltage-gated sodium channel ? subunit. The antibody or antibody fragment thereof is able to inactivate a voltage sensor valve, to make sodium ions unable to enter nerve cells normally, thereby achieving the effect of treating and relieving pains.
Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
October 5, 2021
Assignee:
Just-Evotec Biologics, Inc.
Inventors:
Bruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska
Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.
Type:
Grant
Filed:
May 6, 2020
Date of Patent:
September 21, 2021
Assignee:
Howard Hughes Medical Institute
Inventors:
Scott Sternson, Peter Lee, Christopher Magnus
Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.
Type:
Grant
Filed:
July 7, 2017
Date of Patent:
August 10, 2021
Assignee:
Howard Hughes Medical Institute
Inventors:
Scott Sternson, Peter Lee, Christopher Magnus
Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
Type:
Grant
Filed:
January 10, 2020
Date of Patent:
August 10, 2021
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
Type:
Grant
Filed:
September 25, 2019
Date of Patent:
July 20, 2021
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
Type:
Grant
Filed:
July 22, 2020
Date of Patent:
June 15, 2021
Assignee:
OncoResponse, Inc.
Inventors:
Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Type:
Grant
Filed:
December 6, 2019
Date of Patent:
June 15, 2021
Assignee:
AbbVie Stemcentrx LLC
Inventors:
Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
Abstract: Provided is a long-acting PCSK9-specific binding protein and application thereof. Provided is an MV072 protein with unique complementarity-determining regions, i.e., a binding protein specifically binding to proprotein convertase subtilisin kexin type 9 (PCSK9). The protein can specifically bind to PCSK9, effectively inhibit the function of PCSK9 and reduce plasma LDL cholesterol level. Further provided is an application of the binding protein in treating diseases related to or influenced by the function of PCSK9.
Abstract: The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
Abstract: An object of the present invention is to provide an antibody against VEGF that inhibits binding of a vascular endothelial growth factor (VEGF) to neuropilin-1 (NRP1). The present invention provides an antibody against VEGF that inhibits binding of VEGF to NRP1.
Type:
Grant
Filed:
January 5, 2017
Date of Patent:
May 18, 2021
Assignees:
ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.